Gene-editing stocks rallied after the FDA said it plans to fast-track approvals, with Intellia (NTLA) up +2.9%, Beam (BEAM) +5.1%, CRISPR (CRSP) +4.8%, Editas (EDIT) +2.2%, and Prime Medicine (PRME) +13.8%.
Join our Mailing list!
Sign up to get all the latest financial news and business updates.
Please fill in the form and we will get in touch with you shortly and help answer any questions you may have about Offshore Supporting services.
